Travere Therapeutics, Inc. (TVTX): who owns it and who trades it
As of Nov 16, 2026, TVTX insiders reported 111 open-market sales worth $109M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Eric M Dube (CEO), with $50.8M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Travere Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TVTX
317 funds and institutions reported TVTX shares worth $6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 12.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.32M | 12.18% | $643M | – |
| BlackRock, Inc. | 8.02M | 8.63% | $456M | +3% |
| FMR LLC (Fidelity) | 7.10M | 7.63% | $403M | -35% |
| Bank of America Corp | 4.57M | 4.91% | $260M | +240% |
| State Street Corp | 4.26M | 4.58% | $242M | -14% |
| Vanguard Capital Management LLC | 4.11M | 4.42% | $233M | +2% |
| Perceptive Advisors LLC | 3.75M | 4.04% | $213M | -9% |
| Nomura Asset Management International Inc. | 2.81M | 3.02% | $160M | -14% |
| Adage Capital Partners Gp, L.l.c. | 2.57M | 2.76% | $146M | +163% |
| Geode Capital Management, LLC | 2.37M | 2.55% | $135M | +0% |
| Rock Springs Capital Management LP | 2.18M | 2.34% | $124M | +47% |
| Kynam Capital Management, LP | 2.00M | 2.15% | $114M | +27% |
| Stephens Investment Management Group LLC | 1.88M | 2.02% | $107M | +4% |
| Renaissance Technologies LLC | 1.83M | 1.97% | $104M | -7% |
| Emerald Advisers, LLC | 1.60M | 1.72% | $90.9M | +3% |
| Armistice Capital, LLC | 1.57M | 1.69% | $89.3M | -68% |
| Two Sigma Investments, LP | 1.57M | 1.68% | $88.9M | +4% |
| Vanguard Portfolio Management LLC | 1.54M | 1.66% | $87.6M | -10% |
| Goldman Sachs Group Inc | 1.54M | 1.65% | $87.2M | -11% |
| Wellington Management Group LLP | 1.53M | 1.65% | $87.1M | +50% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TVTX insiders reported $0 of open-market purchases and $109M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Eric M Dube | CEO | Sale plan | 128,065 | $52.97 | $6.8M | Form 4 |
| Oct 15, 2026 | Eric M Dube | CEO | Sale plan | 37,270 | $54.20 | $2M | Form 4 |
| Oct 15, 2026 | Eric M Dube | CEO | Sale plan | 78,400 | $55.02 | $4.3M | Form 4 |
| Sep 17, 2026 | Peter Heerma | Vice president | Sale plan | 8,282 | $65.07 | $539K | Form 4 |
| Sep 17, 2026 | Eric M Dube | CEO | Sale plan | 6,802 | $64.95 | $442K | Form 4 |
| Sep 17, 2026 | Eric M Dube | CEO | Sale plan | 101,691 | $64.59 | $6.6M | Form 4 |
| Sep 16, 2026 | William E. Rote | Chief Research Officer | Sale plan | 65,104 | $63.12 | $4.1M | Form 4 |
| Sep 16, 2026 | William E. Rote | Chief Research Officer | Sale plan | 47,746 | $63.61 | $3M | Form 4 |
| Sep 16, 2026 | Peter Heerma | Vice president | Sale plan | 93,604 | $63.25 | $5.9M | Form 4 |
| Sep 16, 2026 | Peter Heerma | Vice president | Sale plan | 79,113 | $63.65 | $5M | Form 4 |
| Sep 16, 2026 | Eric M Dube | CEO | Sale plan | 99,716 | $63.26 | $6.3M | Form 4 |
| Sep 16, 2026 | Eric M Dube | CEO | Sale plan | 96,125 | $63.64 | $6.1M | Form 4 |
| Sep 15, 2026 | William E. Rote | Chief Research Officer | Sale plan | 63,907 | $61.99 | $4M | Form 4 |
| Sep 15, 2026 | William E. Rote | Chief Research Officer | Sale plan | 29,021 | $62.66 | $1.8M | Form 4 |
| Sep 15, 2026 | William E. Rote | Chief Research Officer | Sale plan | 3,000 | $63.65 | $191K | Form 4 |
| Sep 15, 2026 | William E. Rote | Chief Research Officer | Sale plan | 270 | $65.31 | $17.6K | Form 4 |
| Sep 15, 2026 | Peter Heerma | Vice president | Sale plan | 1,431 | $65.31 | $93.5K | Form 4 |
| Sep 15, 2026 | Peter Heerma | Vice president | Sale plan | 1,400 | $63.65 | $89.1K | Form 4 |
| Sep 15, 2026 | Peter Heerma | Vice president | Sale plan | 27,421 | $62.59 | $1.7M | Form 4 |
| Sep 15, 2026 | Peter Heerma | Vice president | Sale plan | 71,938 | $62.05 | $4.5M | Form 4 |
| Sep 15, 2026 | Jula Inrig | Vice president | Sale plan | 25,390 | $62.02 | $1.6M | Form 4 |
| Sep 15, 2026 | Jula Inrig | Vice president | Sale plan | 400 | $65.31 | $26.1K | Form 4 |
| Sep 15, 2026 | Jula Inrig | Vice president | Sale plan | 1,600 | $63.69 | $102K | Form 4 |
| Sep 15, 2026 | Jula Inrig | Vice president | Sale plan | 17,284 | $62.62 | $1.1M | Form 4 |
| Sep 15, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 1,400 | $63.69 | $89.2K | Form 4 |
| Sep 15, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 300 | $65.31 | $19.6K | Form 4 |
| Sep 15, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 13,874 | $62.63 | $869K | Form 4 |
| Sep 15, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 21,926 | $62.03 | $1.4M | Form 4 |
| Sep 15, 2026 | Eric M Dube | CEO | Sale plan | 63,498 | $61.99 | $3.9M | Form 4 |
| Sep 15, 2026 | Eric M Dube | CEO | Sale plan | 28,796 | $62.66 | $1.8M | Form 4 |
| Sep 15, 2026 | Eric M Dube | CEO | Sale plan | 3,102 | $63.64 | $197K | Form 4 |
| Sep 15, 2026 | Christopher R. Cline | CFO | Sale plan | 27,473 | $62.00 | $1.7M | Form 4 |
| Sep 15, 2026 | Christopher R. Cline | CFO | Sale plan | 20,735 | $62.61 | $1.3M | Form 4 |
| Sep 15, 2026 | Christopher R. Cline | CFO | Sale plan | 1,900 | $63.69 | $121K | Form 4 |
| Sep 15, 2026 | Sandra Calvin | Vice president | Sale plan | 300 | $63.66 | $19.1K | Form 4 |
| Sep 15, 2026 | Sandra Calvin | Vice president | Sale plan | 4,275 | $62.14 | $266K | Form 4 |
| Sep 15, 2026 | Sandra Calvin | Vice president | Sale plan | 800 | $62.85 | $50.3K | Form 4 |
| Sep 10, 2026 | Jeffrey A Meckler | Director | Sale plan | 3,100 | $68.09 | $211K | Form 4 |
| Sep 10, 2026 | Jeffrey A Meckler | Director | Sale plan | 14,000 | $67.46 | $944K | Form 4 |
| Sep 10, 2026 | Jeffrey A Meckler | Director | Sale plan | 1,200 | $66.15 | $79.4K | Form 4 |
| Sep 10, 2026 | Jeffrey A Meckler | Director | Sale plan | 1,700 | $65.39 | $111K | Form 4 |
| Sep 2, 2026 | Christopher R. Cline | CFO | Sale | 642 | $66.37 | $42.6K | Form 4 |
| Aug 18, 2026 | Gary A Lyons | Director | Sale plan | 900 | $63.86 | $57.5K | Form 4 |
| Aug 18, 2026 | Gary A Lyons | Director | Sale plan | 4,100 | $63.27 | $259K | Form 4 |
| Aug 17, 2026 | Gary A Lyons | Director | Sale plan | 1,900 | $62.53 | $119K | Form 4 |
| Aug 17, 2026 | Gary A Lyons | Director | Sale plan | 2,600 | $63.50 | $165K | Form 4 |
| Aug 17, 2026 | Gary A Lyons | Director | Sale plan | 500 | $64.16 | $32.1K | Form 4 |
| Jun 12, 2026 | Timothy Coughlin | Director | Sale plan | 10,000 | $50.07 | $501K | Form 4 |
| Jun 12, 2026 | Roy D. Baynes | Director | Sale plan | 4,500 | $50.00 | $225K | Form 4 |
| May 15, 2026 | Timothy Coughlin | Director | Sale plan | 3,250 | $43.49 | $141K | Form 4 |
| May 6, 2026 | William E. Rote | Chief Research Officer | Sale plan | 2,763 | $43.95 | $121K | Form 4 |
| May 6, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 2,076 | $43.95 | $91.2K | Form 4 |
| May 6, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale plan | 311 | $43.95 | $13.7K | Form 4 |
| May 6, 2026 | Eric M Dube | CEO | Sale plan | 22,500 | $43.95 | $989K | Form 4 |
| May 6, 2026 | Christopher R. Cline | CFO | Sale plan | 310 | $43.95 | $13.6K | Form 4 |
| May 5, 2026 | Roy D. Baynes | Director | Sale plan | 4,500 | $46.65 | $210K | Form 4 |
| May 5, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 2,174 | $46.65 | $101K | Form 4 |
| May 5, 2026 | Christopher R. Cline | CFO | Sale plan | 2,181 | $46.65 | $102K | Form 4 |
| May 4, 2026 | Jeffrey A Meckler | Director | Sale plan | 8,000 | $45.00 | $360K | Form 4 |
| May 4, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 20,000 | $45.00 | $900K | Form 4 |
| May 1, 2026 | Roy D. Baynes | Director | Sale plan | 9,750 | $44.22 | $431K | Form 4 |
| Apr 22, 2026 | William E. Rote | Chief Research Officer | Sale plan | 9,100 | $39.09 | $356K | Form 4 |
| Apr 15, 2026 | Eric M Dube | CEO | Sale plan | 56,815 | $41.01 | $2.3M | Form 4 |
| Apr 15, 2026 | Eric M Dube | CEO | Sale plan | 20 | $42.66 | $853 | Form 4 |
| Apr 15, 2026 | Eric M Dube | CEO | Sale plan | 7,165 | $41.75 | $299K | Form 4 |
| Apr 15, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 1,559 | $42.53 | $66.3K | Form 4 |
| Apr 15, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 5,226 | $41.62 | $218K | Form 4 |
| Apr 15, 2026 | Christopher R. Cline | CFO | Sale plan | 1,014 | $42.61 | $43.2K | Form 4 |
| Apr 15, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale plan | 1,018 | $42.61 | $43.4K | Form 4 |
| Apr 14, 2026 | Gary A Lyons | Director | Sale plan | 8,000 | $41.07 | $329K | Form 4 |
| Apr 14, 2026 | Roy D. Baynes | Director | Sale plan | 26,000 | $41.07 | $1.1M | Form 4 |
| Apr 14, 2026 | Roy D. Baynes | Director | Sale plan | 6,750 | $42.12 | $284K | Form 4 |
| Apr 14, 2026 | Sandra Calvin | Vice president | Sale plan | 21,977 | $41.07 | $903K | Form 4 |
| Apr 14, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale | 7,215 | $41.93 | $303K | Form 4 |
| Apr 14, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 37,500 | $41.07 | $1.5M | Form 4 |
| Apr 14, 2026 | Christopher R. Cline | CFO | Sale plan | 7,239 | $41.93 | $304K | Form 4 |
| Apr 14, 2026 | Christopher R. Cline | CFO | Sale plan | 9 | $41.07 | $370 | Form 4 |
| Apr 13, 2026 | Christopher R. Cline | CFO | Sale plan | 65 | $28.85 | $1.9K | Form 4 |
| Apr 6, 2026 | Roy D. Baynes | Director | Sale plan | 10,000 | $33.00 | $330K | Form 4 |
| Apr 1, 2026 | Eric M Dube | CEO | Sale plan | 25,098 | $31.46 | $790K | Form 4 |
| Apr 1, 2026 | Eric M Dube | CEO | Sale plan | 34,902 | $30.55 | $1.1M | Form 4 |
| Apr 1, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 10,000 | $30.00 | $300K | Form 4 |
| Mar 16, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 10,000 | $28.09 | $281K | Form 4 |
| Feb 20, 2026 | Eric M Dube | CEO | Sale plan | 60,000 | $30.10 | $1.8M | Form 4 |
| Feb 17, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 4,321 | $28.26 | $122K | Form 4 |
| Feb 17, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 5,679 | $27.50 | $156K | Form 4 |
| Feb 4, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 509 | $32.74 | $16.7K | Form 4 |
| Feb 4, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale plan | 2,485 | $32.07 | $79.7K | Form 4 |
| Feb 4, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale plan | 232 | $32.85 | $7.6K | Form 4 |
| Feb 4, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale plan | 1,547 | $32.11 | $49.7K | Form 4 |
| Feb 4, 2026 | Christopher R. Cline | CFO | Sale plan | 110 | $32.90 | $3.6K | Form 4 |
| Feb 4, 2026 | Christopher R. Cline | CFO | Sale plan | 1,635 | $32.14 | $52.5K | Form 4 |
| Feb 3, 2026 | Eric M Dube | CEO | Sale plan | 33,635 | $32.70 | $1.1M | Form 4 |
| Feb 3, 2026 | Eric M Dube | CEO | Sale plan | 66,452 | $32.06 | $2.1M | Form 4 |
| Feb 3, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | Sale | 6,956 | $32.12 | $223K | Form 4 |
| Feb 3, 2026 | Christopher R. Cline | CFO | Sale | 7,242 | $32.12 | $233K | Form 4 |
| Feb 3, 2026 | Peter Heerma | CHIEF COMMERCIAL OFFICER | Sale | 7,310 | $32.12 | $235K | Form 4 |
| Feb 3, 2026 | William E. Rote | Chief Research Officer | Sale plan | 12,446 | $32.87 | $409K | Form 4 |
| Feb 3, 2026 | Elizabeth E Reed | Chief Legal Officer and | Sale | 7,175 | $32.12 | $230K | Form 4 |
| Feb 3, 2026 | Sandra Calvin | Vice president | Sale | 4,333 | $32.12 | $139K | Form 4 |
Latest 100 of 111 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Eric M Dube | CHIEF EXECUTIVE OFFICER, Director | – | $50.8M | Oct 15, 2026 |
| Peter Heerma | CHIEF COMMERCIAL OFFICER | – | $18.6M | Sep 17, 2026 |
| William E. Rote | Chief Research Officer | – | $16.4M | Sep 16, 2026 |
| Elizabeth E Reed | Chief Legal Officer and GC | – | $6.7M | Sep 15, 2026 |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | – | $4.6M | Sep 15, 2026 |
| Jula Inrig | CHIEF MEDICAL OFFICER | – | $3.9M | Sep 15, 2026 |
| Roy D. Baynes | Director | – | $2.5M | Jun 12, 2026 |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | – | $1.8M | Sep 15, 2026 |
| Jeffrey A Meckler | Director | – | $1.7M | Sep 10, 2026 |
| Gary A Lyons | Director | – | $961K | Aug 18, 2026 |
| Timothy Coughlin | Director | – | $642K | Jun 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TVTX short interest
Moderate short interest. 10.0% of TVTX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.56M TVTX shares were sold short, 10.0% of the shares outstanding, down 12.4% from the report before. At the average daily volume of 2.02M shares, buying them all back would take about 4.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.56M | 9.96% | -12% | 2.02M | 4.7 |
| Oct 15, 2026 | 10.91M | 11.58% | -14% | 2.08M | 5.2 |
| Sep 30, 2026 | 12.66M | 13.43% | -2% | 1.75M | 7.2 |
| Sep 15, 2026 | 12.96M | 13.74% | +8% | 1.25M | 10.4 |
| Aug 31, 2026 | 12.00M | 12.74% | +1% | 1.26M | 9.6 |
| Aug 14, 2026 | 11.94M | 12.67% | +2% | 2.10M | 5.7 |
| Jul 31, 2026 | 11.68M | 12.39% | -3% | 1.24M | 9.4 |
| Jul 15, 2026 | 12.02M | 12.92% | -5% | 1.31M | 9.2 |
| Jun 30, 2026 | 12.69M | 13.64% | -6% | 2.69M | 4.7 |
| Jun 15, 2026 | 13.44M | 14.45% | -5% | 2.10M | 6.4 |
| May 29, 2026 | 14.12M | 15.19% | +1% | 1.73M | 8.2 |
| May 15, 2026 | 14.01M | 15.06% | -1% | 3.13M | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Travere Therapeutics company events
Travere Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Sep 21, 2026LeadershipTravere Therapeutics, Inc. and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the Company effective… Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jul 9, 2026LeadershipSandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027. Filing
- Jun 16, 2026LeadershipWilliam Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027, the 10 year anniversary of his employment with the Company. Filing
- Jun 2, 2026AgreementTravere Therapeutics, Inc. entered into a license and collaboration agreement with Everest Medicines (Singapore) Pte. Filing
- May 21, 2026LeadershipAs discussed below in Item 5.07, Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by… Filing
- May 11, 2026AgreementTravere Therapeutics, Inc. completed its registered underwritten public offering of $525.0 million of 0.50% Convertible Senior Notes due 2032 (such notes, the “Notes,” and such offering, the “Offering”) pursuant to the underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC and… Filing
- May 4, 2026ResultsReleased financial results. Filing
- Apr 14, 2026AnnouncementTravere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Jan 13, 2026AnnouncementTravere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has extended the review timeline of its supplemental New Drug Application for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Travere Therapeutics financials
Famous investors that hold TVTX
5 of the 50 well-known investors we track reported holding TVTX in their latest 13F filing. The largest position is Jim Simons's, worth $63.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.08M | $63.5M | 0.1% | -41% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 441,372 | $26M | 0.0% | -8% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 66,271 | $3.9M | 0.0% | +72% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 14,247 | $839K | 0.0% | -10% |
| Israel Englander · Millennium Management | Q3 2026 | 8,116 | $478K | 0.0% | -90% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TVTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 7.1% |
| Nov 16, 2026 | BANK OF AMERICA CORP /DE/ | 13G/A | 7.1% |
| Nov 5, 2026 | FMR LLC | 13G/A | 6.1% |
| Nov 5, 2026 | FMR LLC | 13G/A | 6.1% |
Questions about Travere Therapeutics, Inc. (TVTX) stock
Who owns the most TVTX stock?
The largest reported owner of Travere Therapeutics, Inc. (TVTX) is Jupiter Topco LLC, with 12.2% of the company. In total, 317 funds and institutions reported holding TVTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are TVTX insiders buying or selling?
In the last 12 months, TVTX insiders reported no open-market purchases and 111 sales worth $109M. The latest trade was on Oct 15, 2026. See every trade.
What is the short interest in TVTX?
As of Oct 30, 2026, 9.56M TVTX shares were sold short, 10.0% of the shares outstanding, down 12.4% from the report before. At the average daily volume of 2.02M shares, buying them all back would take about 4.7 trading days (days to cover). See the history.
Which famous investors hold TVTX?
5 of the 50 well-known investors we track reported TVTX in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $63.5M. See all holders.
Executive pay
Travere Therapeutics's chief executive was paid a total of $8.5M for the year ended Dec 31, 2025, up 62% from $5.2M the year before. In the last 12 months, Travere Therapeutics's executives and directors bought no stock on the open market and sold $109M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.